Transaction DateRecipientSharesTypePriceValue
24th October 2020Beth C Seidenberg7,000Grant/award etc.$0.00
1st October 2020Kevin T Conroy9,391Open or private sale$103.57$972,625.87
1st October 2020Kevin T Conroy5,200Open or private sale$104.70$544,440.00
1st October 2020Kevin T Conroy11,698Open or private sale$102.86$1,203,256.28
1st October 2020Kevin T Conroy1,136Open or private sale$105.20$119,507.20
30th September 2020David M Mott1,965Grant/award etc.$11.93$23,442.45
30th September 2020Kevin T Conroy933Grant/award etc.$11.93$11,130.69
2nd September 2020Joseph Beaulieu543Open or private sale$12.88$6,993.84
1st September 2020Kevin T Conroy19,927Open or private sale$75.03$1,495,122.81
20th August 2020Paolo Tombesi2,091Payment by withholding$12.55$26,242.05
Epizyme logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007.

Ticker: EPZM
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1571498
Employees: 203
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $117 M (0%)
Marketable Securities, Current: $205 M (-15%)
Assets, Current: $355 M (-11%)
Property, Plant and Equipment, Net: $2 M (2%)
Other Assets, Noncurrent: $2 M (-3%)
Assets: $427 M (0%)
Accounts Payable, Current: $5 M (-47%)
Accrued Liabilities, Current: $22 M (0%)
Liabilities, Current: $31 M (-10%)
Other Liabilities, Noncurrent: $21 Th (-44%)
Common Stock, Value, Issued: $10 Th (0%)
Common Stock, Shares, Issued: $101 Th (3%)
Retained Earnings (Accumulated Deficit): $866 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $460 Th (2321%)
Stockholders' Equity (Parent): $293 M (0%)
Liabilities and Equity: $427 M (0%)
Research and Development: $26 M (-48%)
Operating Income/Loss: $58 M (-47%)
EPS (basic): $0.58 (-46%)
EPS (diluted): $0.58 (-46%)